Eovist® is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.
In addition to dynamic-phase imaging, Eovist® specifically targets functioning hepatocytes within the liver providing additional morphological and functional images about lesion cell composition.1,2
How Eovist®, a hepatobiliary agent, works2
- Following Injection, Eovist® is equally eliminated through the renal and hepatic systems
- Eovist® is initially distributed in the extracellular space, allowing for arterial, portal venous, and transitional imaging phase1,3
- Further assessment of lesions through hepatobiliary phase imaging at 20 minutes post injection:
- Lesions with little or no hepatobiliary function will generally not accumulate Eovist®
- Lesions with normal hepatobiliary function will accumulate Eovist®